Unknown

Dataset Information

0

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.


ABSTRACT: Stimulator of interferon genes (STING) signaling induces IFN? production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigen-specific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2+ breast tumors. ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100% of nontolerant parental FVB/N mice. In contrast, ADU S-100 did not sufficiently prime HER-2-specific CD8+ T cells in tolerant neu/N mice, resulting in only delayed tumor growth and tumor clearance in 10% of the mice. No differences in IFN? production, DC priming, or HER-2-specific CD8+ T-cell trafficking were detected between FVB/N and neu/N mice. However, activation and expansion of HER-2-specific CD8+ T cells were defective in neu/N mice. Immune cell infiltrates of untreated tumor-bearing neu/N mice expressed high numbers of PD1 and OX40 receptors on their CD8+ T cells, and PD-L1 was highly expressed on both myeloid and tumor cells. Modulating PD-L1 and OX40 receptor signaling combined with intratumoral ADU S-100 administration enhanced HER-2-specific CD8+ T-cell activity, clearing tumors in 40% of neu/N mice. Thus, intratumoral STING agonists could potently prime tumor antigen-specific CD8+ T-cell responses, and adding PD-L1 blockade and OX40 receptor activation can overcome antigen-enforced immune tolerance to induce tumor regression. Cancer Immunol Res; 5(6); 468-79. ©2017 AACR.

SUBMITTER: Foote JB 

PROVIDER: S-EPMC5550830 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote Jeremy B JB   Kok Marleen M   Leatherman James M JM   Armstrong Todd D TD   Marcinkowski Bridget C BC   Ojalvo Laureen S LS   Kanne David B DB   Jaffee Elizabeth M EM   Dubensky Thomas W TW   Emens Leisha A LA  

Cancer immunology research 20170508 6


Stimulator of interferon genes (STING) signaling induces IFNβ production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigen-specific tolerance influenced the efficacy of <i>in situ</i> delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2<sup>+</sup> breast tumors. ADU S-100 induced HER-2-specific CD8<sup>+</sup> T-cell priming and durabl  ...[more]

Similar Datasets

| S-EPMC9156412 | biostudies-literature
| S-EPMC9207558 | biostudies-literature
| S-EPMC10040386 | biostudies-literature
| S-EPMC3033230 | biostudies-literature
| S-EPMC9322647 | biostudies-literature
| S-EPMC4294117 | biostudies-literature
| S-EPMC8397682 | biostudies-literature
| S-EPMC4504692 | biostudies-literature
| S-EPMC9185610 | biostudies-literature
| S-EPMC5790389 | biostudies-literature